Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTV + PD-1/L1 inhibitor in advanced solid tumours
NCT06430502Recruiting
- Sponsor
- Wuxi People's Hospital
- Start
- May 2024
- Primary completion
- Jun 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of Tumor Treatment Vaccine in solid tumor (advanced stage), sponsored by Wuxi People's Hospital. Primary endpoint: Relief degree of tumors. Started May 2024; status: recruiting.
02
Drugs
Tumor Treatment Vaccine
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06430502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06430502.